Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis
Liver International · 2025
DOI: 10.1111/liv.70092 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Liver International, 2025. Verfasst von Federico Piñero und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Austral, Pilar, Argentina. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background and Aims The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first‐line systemic therapies remain unclear. We compared survival from the initiation of first‐line systemic treatments for advanced HCC among patients with compensated, decompensated, and recompensated cirrhosis.
Methods
A Latin American multicenter, prospective cohort study was conducted from 2018 to 2024, involving patients with HCC and Child‐Pugh class A or B who received systemic therapy. At the time of first‐line therapy, patients with cirrhosis were categorised as compensated (never decompensated), decompensated, or recompensated. Cox proportional hazards models were estimated.
Results
Among 306 patients receiving first‐line systemic therapy (sorafenib: 60.5%, atezolizumab + bevacizumab: 29.7%, lenvatinib: 9.1%), 240 had cirrhosis, with 30.4% having a history of hepatic decompensation. Of these, 57.5% (95% CI 45.4%–69.0%) achieved hepatic recompensation over a median period of 12 months. At the time of first‐line therapy, 69.6% were compensated, 17.5% recompensated, and 12.9% decompensated. Metabolic‐associated steatotic liver disease (MASLD) was the most common underlying aetiology in the recompensated group. Median survival was significantly shorter in the decompensated group (8.6 months) compared to the compensated group (17.2 months) [aHR 1.91 (95% CI 1.04–3.5); p = 0.03], without a significant difference between the recompensated and compensated groups [aHR 1.28 (95% CI 0.79–2.1); p = 0.31]. Tumour progression was the primary reason for treatment discontinuation, and similar access to second‐line therapies was observed between the compensated and recompensated groups.
Conclusion
Patients with cirrhosis and advanced HCC who achieved hepatic recompensation might benefit from systemic therapies after a cautious observation period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Austral, Pilar, Argentina.
- Hospital Alemán, Buenos Aires, Argentina.
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
- Sanatorio Sagrado Corazón, Buenos Aires, Argentina.
- Fundación Cardioinfantil, Bogotá, Colombia.
- Hospital Padilla, Tucumán, Argentina.
ORCID-Profile: Federico Piñero, Margarita Anders, Carla Bermudez, Diego Arufe, Ana Palazzo, Daniela Simian, Leonardo Gomes da Fonseca, Ezequiel Ridruejo, Hugo Cheinquer, Diana Bejarano, Josefina Pages, Jaime Poniachik, Sebastián Marciano, Virginia Reggiardo, Marcelo Silva, Manuel Mendizabal
Zitieren
APA
Piñero, F., Anders, M., Bermudez, C., Arufe, D., Varón, A., Palazzo, A., Rodriguez, J., Beltrán, O., Simian, D., da Fonseca, L. G., Ridruejo, E., Tamagnone, N., Cheinquer, H., Bejarano, D., Marín, J. I., Orozco, F., Pages, J., Poniachik, J., Marciano, S., …, & Mendizabal, M. (2025). Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis. Liver International. https://doi.org/10.1111/liv.70092
Vancouver
Piñero F, Anders M, Bermudez C, Arufe D, Varón A, Palazzo A, et al. Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis. Liver International. 2025. doi:10.1111/liv.70092
BibTeX
@article{Piero2025,
author = {Piñero, Federico and Anders, Margarita and Bermudez, Carla and Arufe, Diego and Varón, Adriana and Palazzo, Ana and Rodriguez, Jorge and Beltrán, Oscar and Simian, Daniela and da Fonseca, Leonardo Gomes and Ridruejo, Ezequiel and Tamagnone, Norberto and Cheinquer, Hugo and Bejarano, Diana and Marín, Juan Ignacio and Orozco, Federico and Pages, Josefina and Poniachik, Jaime and Marciano, Sebastián and Reggiardo, Virginia and Silva, Marcelo and Mendizabal, Manuel},
title = {Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70092}
}
EUVIMED